Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Lymphoma Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Lymphoma

Protocol Alliance A051301
Cancer Type: Lymphoma
Fast Facts

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1925
Cancer Type: CLL/SLL
Fast Facts

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ANHL1931
Cancer Type: Lymphoma
Fast Facts

COG ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

This is an AYA protocol  ≥ 2 years

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A051701
Cancer Type: Double-hit and double-expressing lymphomas
Fast Facts

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1608
Cancer Type: FOLLICULAR LYMPHOMA
Fast Facts

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA4181
Cancer Type: Untreated Mantle Cell lymphoma
Fast Facts

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <70 years old with Untreated Mantle Cell Lymphoma 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1826
Cancer Type: ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Fast Facts

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.